Radius Health, Inc. (NASDAQ:RDUS) Stock Rating Reaffirmed by Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their buy rating on shares of Radius Health, Inc. (NASDAQ:RDUS) in a research note issued to investors on Friday, November 3rd. The firm currently has a $58.00 target price on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the company. Canaccord Genuity set a $85.00 price target on Radius Health and gave the company a buy rating in a report on Monday, July 17th. BidaskClub downgraded Radius Health from a hold rating to a sell rating in a report on Friday, August 11th. Jefferies Group LLC reissued a hold rating and issued a $38.00 price target (up previously from $34.00) on shares of Radius Health in a report on Wednesday, August 9th. Zacks Investment Research raised Radius Health from a sell rating to a hold rating in a report on Tuesday, August 8th. Finally, Maxim Group reaffirmed a positive rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $51.00.

Shares of Radius Health (RDUS) opened at $27.71 on Friday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87. Radius Health has a 12 month low of $27.16 and a 12 month high of $55.97.

Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The firm had revenue of $13.50 million during the quarter, compared to analyst estimates of $6.90 million. During the same period in the prior year, the business posted ($1.07) EPS. sell-side analysts predict that Radius Health will post -5.4 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.truebluetribune.com/2017/11/14/radius-health-inc-rdus-stock-rating-reaffirmed-by-cantor-fitzgerald.html.

In other Radius Health news, VP Brent Hatzis-Schoch bought 1,778 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were purchased at an average cost of $28.09 per share, for a total transaction of $49,944.02. Following the transaction, the vice president now directly owns 2,278 shares in the company, valued at $63,989.02. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jesper Hoiland purchased 6,800 shares of the stock in a transaction dated Tuesday, November 7th. The shares were purchased at an average price of $29.04 per share, for a total transaction of $197,472.00. Following the completion of the transaction, the insider now owns 12,900 shares in the company, valued at approximately $374,616. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 427,678 shares of company stock worth $14,430,298. 15.00% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the company. Sei Investments Co. increased its position in shares of Radius Health by 27.7% during the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 690 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Radius Health by 19.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 541 shares during the period. Advisor Group Inc. increased its position in shares of Radius Health by 267.2% during the 2nd quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,888 shares during the period. Blair William & Co. IL acquired a new position in shares of Radius Health during the 2nd quarter valued at $205,000. Finally, Amalgamated Bank acquired a new position in shares of Radius Health during the 2nd quarter valued at $211,000.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply